LEXINGTON, Mass., March 10, 2021 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
of innovative therapeutics for the treatment of cancer, today
announced that an abstract for CA-4948, a small molecule IRAK4
inhibitor, has been accepted for poster presentation at the
American Association for Cancer Research (AACR) Annual Meeting,
which will be held virtually from April
Details of the presentation are as follows:
- Title: Identification of NF-kappaB phospho-p50 as a
Potential Predictive Biomarker for IRAK4 inhibitor CA-4948 in
Patients with Non-Hodgkin's Lymphoma
- Session Name: Biomarkers Predictive of Therapeutic
- Session Date: Saturday, April 10,
Additional meeting information can be found on the AACR website
presentation will also be available under "Events and
Presentations" in the Investors section of the Company's website at
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently
undergoing testing in a Phase 1 trial in patients with
non-Hodgkin's lymphoma both as a monotherapy and in combination
with BTK inhibitor, ibrutinib. Curis is also evaluating CA-4948 in
a Phase 1 trial in patients with acute myeloid leukemia and
myelodysplastic syndromes. In addition, Curis is engaged in a
collaboration with ImmuNext for development of CI-8993, a
monoclonal anti-VISTA antibody, which is currently undergoing
testing in a Phase 1a/1b trial in
patients with solid tumors. Curis is also party to a collaboration
with Genentech, a member of the Roche Group, under which Genentech
and Roche are commercializing Erivedge® for the treatment of
advanced basal cell carcinoma. For more information, visit Curis'
website at www.curis.com.
View original content to download
SOURCE Curis, Inc.